4599.T
StemRIM Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 146.00
−0.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 2.4B | 22.0M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | — | — | — | — | — |
| Cost and Expenses | — | — | — | 2.2B | 2.0B |
| Operating Income (EBIT) | (1.9B) | (2.0B) | (2.1B) | 142.0M | (2.0B) |
| Non-Operating | |||||
| Interest Income | 9.7M | — | — | — | — |
| Interest Expense | — | — | 1.0K | 58.0K | 140.0K |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 11.9M | 1.1M | (1.8M) | 3.0M | 8.4M |
| Non-Operating Income (excl Interest) | 1.7M | — | — | 645.0K | 5.0K |
| EBT (Pre-Tax Income) | (1.9B) | (1.9B) | (2.0B) | 170.2M | (1.9B) |
| Income Tax Expense | 1.7M | 1.7M | 3.3M | 1.9M | 2.1M |
| Bottom Line | |||||
| Net Income | (1.9B) | (1.9B) | (2.0B) | 168.0M | (1.9B) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.9B) | (1.9B) | (2.0B) | 168.0M | (1.9B) |
| Per Share | |||||
| Basic EPS | (¥31) | (¥31) | (¥33) | ¥3 | (¥33) |
| Diluted EPS | (¥31) | — | — | ¥3 | — |
| Revenue Per Share | — | — | — | ¥39 | ¥0 |
| Shares | |||||
| Basic Shares Outstanding | 62.1M | 61.9M | 61.3M | 60.1M | 59.2M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | (903.5M) | (1.9B) | (2.0B) | 189.8M | (1.9B) |
| D&A | 49.5M | 49.5M | 44.3M | 47.8M | 49.5M |
| EBIT | (1.9B) | (2.0B) | (2.1B) | 142.0M | (2.0B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jan 1, 2026